Clinical Trialist Training Program

Medical School: Emory University

Residency: Internal Medicine - Beth Israel Deaconess Medical Center, Harvard Medical School

Residency: Pediatrics - St. Louis Children's Hospital, Washington University

Fellowship: Washington University

Additional Training: Epidemic Intelligence Service Fellowship - Centers for Disease Control and Prevention; Master of Public Health in Epidemiology - Emory University

Dr. Rhea Hans is a pediatric bone marrow transplant physician with a special focus on cellular and gene therapies. She cares for children with blood disorders, immune deficiencies, and both hematologic and solid malignancies. Her clinical interests include advancing access to bone marrow and stem cell transplantation as well as developing new treatment approaches through clinical trials.

Dr. Hans completed her medical degree at St. George's University followed by residency training in pediatrics at Newark Beth Israel Medical Center and fellowship training in pediatric hematology/oncology at Phoenix Children's Hospital. She went on to receive additional specialized training in pediatric bone marrow transplantation at Memorial Sloan Kettering Cancer Center, where she developed expertise in cellular therapy and the use of gene therapy for inherited and acquired conditions.

In her role at MUSC, Dr. Hans is excited to expand the pediatric bone marrow transplant and gene therapy programs, with the goal of offering children in South Carolina and beyond access to cutting-edge treatments close to home. She is particularly passionate about bringing novel clinical trials to her patients and working as part of a collaborative, multidisciplinary team to deliver the best possible outcomes.

Outside of her clinical work, Dr. Hans is involved in community outreach and education to raise awareness about childhood cancers and the importance of bone marrow donation. She is committed to building strong relationships with families, providing compassionate care, and guiding them through every step of their child's treatment journey.

Dr. Andrew Goodwin is a pulmonary intensivist committed to improving the health and well-being of critically ill patients through patient-centered care and clinical and translational research. His clinical interests include the hemodynamic management of septic shock and ventilation strategies for ARDS as well as strategies to mitigate ICU delirium. He also performs translational research focused on the potential role that micro RNA play in the endothelial dysfunction of sepsis and ARDS. In particular, he and his collaborators are focused on identifying the role that circulating miRNA have on endothelial cell gene expression and function and their potential use as a therapeutic in these syndromes. Additionally, he investigates the impact of patient factors such as race and comorbidities as well as hospital factors such as location and size on the outcomes of critical illness. His long-range goal is to improve the outcomes of critically ill patients through new therapeutics and optimal bedside care.